

Ymkje Anna de Vries

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9374341/publications.pdf>

Version: 2024-02-01

30
papers

696
citations

623188

14
h-index

580395

25
g-index

33
all docs

33
docs citations

33
times ranked

1103
citing authors

#	ARTICLE	IF	CITATIONS
1	Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. <i>BMC Medicine</i> , 2020, 18, 21.	2.3	132
2	Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders. <i>JAMA Psychiatry</i> , 2015, 72, 500.	6.0	92
3	Comorbidity within mental disorders: a comprehensive analysis based on 145 990 survey respondents from 27 countries. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e153.	1.8	67
4	The cumulative effect of reporting and citation biases on the apparent efficacy of treatments: the case of depression. <i>Psychological Medicine</i> , 2018, 48, 2453-2455.	2.7	53
5	Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression. <i>British Journal of Psychiatry</i> , 2016, 208, 515-521.	1.7	34
6	Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. <i>PLoS Medicine</i> , 2022, 19, e1003886.	3.9	31
7	Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. <i>British Journal of Psychiatry</i> , 2019, 214, 4-10.	1.7	26
8	Citation bias and selective focus on positive findings in the literature on the serotonin transporter gene (5-HTTLPR), life stress and depression. <i>Psychological Medicine</i> , 2016, 46, 2971-2979.	2.7	25
9	Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials. <i>Psychological Medicine</i> , 2019, 49, 2020-2026.	2.7	25
10	Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis. <i>European Neuropsychopharmacology</i> , 2016, 26, 1752-1759.	0.3	24
11	Childhood generalized specific phobia as an early marker of internalizing psychopathology across the lifespan: results from the World Mental Health Surveys. <i>BMC Medicine</i> , 2019, 17, 101.	2.3	24
12	A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys. <i>Depression and Anxiety</i> , 2019, 36, 499-510.	2.0	22
13	Citation Distortions in the Literature on the Serotonin-Transporter-Linked Polymorphic Region and Amygdala Activation. <i>Biological Psychiatry</i> , 2015, 78, E35-E36.	0.7	20
14	Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 624-633.	0.7	19
15	Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. <i>World Psychiatry</i> , 2022, 21, 272-286.	4.8	16
16	The antidepressant standoff: why it continues and how to resolve it. <i>Psychological Medicine</i> , 2020, 50, 177-186.	2.7	15
17	Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis. <i>Depression and Anxiety</i> , 2018, 35, 515-522.	2.0	11
18	Poor guideline adherence in the initiation of antidepressant treatment in children and adolescents in the Netherlands: choice of antidepressant and dose. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 1161-1170.	2.8	10

#	ARTICLE	IF	CITATIONS
19	Perceived helpfulness of treatment for specific phobia: Findings from the World Mental Health Surveys. <i>Journal of Affective Disorders</i> , 2021, 288, 199-209.	2.0	9
20	Hormonal contraceptive use and depressive symptoms: systematic review and network meta-analysis of randomised trials. <i>BJPsych Open</i> , 2021, 7, e110.	0.3	9
21	Statistical power in clinical trials of interventions for mood, anxiety, and psychotic disorders. <i>Psychological Medicine</i> , 2023, 53, 4499-4506.	2.7	8
22	The relationship between mental disorders and actual and desired subjective social status. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e83.	1.8	6
23	Rethinking remdesivir for COVID-19: A Bayesian reanalysis of trial findings. <i>PLoS ONE</i> , 2021, 16, e0255093.	1.1	6
24	A Prescription Trend Analysis of Methylphenidate: Relation to Study Reports on Efficacy. Administration and Policy in Mental Health and Mental Health Services Research, 2020, 47, 291-299.	1.2	4
25	Previous disorders and depression outcomes in individuals with 12-month major depressive disorder in the World Mental Health surveys. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e70.	1.8	3
26	Intermittent explosive disorder subtypes in the general population: association with comorbidity, impairment and suicidality. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e138.	1.8	2
27	Transdiagnostic development of internalizing psychopathology throughout the life course up to age 45: a World Mental Health Surveys report. <i>Psychological Medicine</i> , 2020, , 1-10.	2.7	1
28	Comparing the evidential strength for psychotropic drugs: a Bayesian meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 2752-2761.	2.7	1
29	Letter to the Editor: Moving science forward by increasing awareness of reporting and citation biases: a reply to Vrshek-Schallhorn et al. (2016). <i>Psychological Medicine</i> , 2017, 47, 183-185.	2.7	0
30	The potential of individual patient data for research on antidepressant safety and efficacy. <i>European Neuropsychopharmacology</i> , 2017, 27, 695-696.	0.3	0